Bausch + Lomb (BLCO) Reports Record Q4 2025 Financial Results Driven by Strong Pharmaceutical and Vision Care Growth

Core Insights - Bausch + Lomb Corporation reported record financial results for Q4 2025, with revenue increasing by 7% to $1.405 billion and adjusted EBITDA rising by 27% to $330 million, contributing to a full-year revenue of $5.101 billion driven by a diversified portfolio [1][3] Financial Performance - The pharmaceutical segment experienced a 14% growth in Q4, while the Vision Care division, bolstered by an 8% increase in contact lens sales, generated $778 million in revenue for the quarter [1] - The dry eye treatment Miebo was a standout performer, with Q4 revenue soaring by 111% to $112 million, attributed to marketing investments and a strong sales force [2] - The surgical segment achieved a 20% growth in premium intraocular lenses, recovering from a previous product recall [2] Future Outlook - For 2026, the company aims to maintain its adjusted EBITDA margin at 23.5% through operational execution and financial discipline, despite competitive pressures in the IOL and contact lens markets [4] - Bausch + Lomb anticipates continued outperformance of its daily SiHy lenses in the global market and expects mid-single-digit sales growth for Xiidra as net pricing stabilizes [4] Company Overview - Bausch + Lomb operates in the eye health sector across multiple countries, including the US, Canada, and various international markets, with three main segments: Vision Care, Pharmaceuticals, and Surgical [5]